Pharmaceutical companies Merck, known as MSD in Europe, and Moderna have announced that a personalised cancer vaccine has significantly improved outcomes for melanoma patients.
The announcement raises the question of whether the era of cancer vaccines has arrived. Cancer cell biologist Anne Willis from the Medical Research Council is set to discuss the implications.